About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

( MENAFN - Investor Ideas) Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech and medical tech Stocks reports on trading and news for Aethlon Medical, Inc ...

Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...

Kazia Therapeutics is at the forefront of developing cutting-edge cancer therapies, with a key focus on brain cancer and aggressive tumor types like triple-negative breast cancer. The company’s ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.